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Letters
Reduction in First and
Total Ischemic Events
With Icosapent Ethyl
Across Baseline
Triglyceride Tertiles
Triglyceride elevation has re-emerged as a potent
marker of residual cardiovascular risk in statin-
treated patients (1). Converging lines of evidence
from epidemiological analyses, Mendelian randomi-
zation studies, and outcome data from REDUCE-IT
(Reduction of Cardiovascular Events with
EPA-Intervention Trial) support even moderately
elevated triglycerides as being associated with
increased cardiovascular risk and as a potential target
of therapy (1,2).
REDUCE-IT randomized 8,179 statin-treated pa-
tients with triglycerides $135 and <500 mg/dl (me-
dian baseline of 216 mg/dl); low-density lipoprotein
(LDL) cholesterol >40 and #100 mg/dl (median
baseline of 75 mg/dl); and with a history of athero-
sclerosis (coronary, cerebral, or peripheral) or
with diabetes and other risk factors to icosapent
ethyl 4 g/day or placebo (3,4). Patients were followed
for a median of 4.9 years. The primary endpoint, a
composite of cardiovascular death, nonfatal myocar-
dial infarction, nonfatal stroke, coronary revascular-
ization, or hospitalization for unstable angina, was
reduced by 25% (hazard ratio: 0.75; 95% conﬁdence
interval: 0.68 to 0.83; p < 0.0001). In a pre-speciﬁed
analysis, total primary endpoint events (ﬁrst and
subsequent events) were signiﬁcantly reduced by
30% (rate ratio: 0.70; 95% CI: 0.62 to 0.78; p < 0.0001)
(5). Here, we examined by pre-speciﬁed baseline tri-
glyceride tertiles the primary endpoint of ﬁrst event
(Cox proportional-hazards model) and total events
(negative binomial regression model). REDUCE-IT
inclusion criteria speciﬁed fasting triglycerides $135
and <500 mg/dl at screening, although lower or
higher triglycerides were possible at baseline, which
was an average of screening and randomization visits.
Baseline triglycerides ranged from 81 to 1,401 mg/dl.
Median triglycerides across ascending tertiles were
163, 217, and 304 mg/dl. There were large, consistent,
statistically signiﬁcant reductions with icosapent
ethyl in the primary endpoint for ﬁrst (Figure 1A) and
total events (Figure 1B) across all tertiles. Elevated
risk occurs at lower triglyceride levels than previously
appreciated. While placebo event rates were highest
in the upper tertile, where a numerically larger rela-
tive risk reduction was suggested, cross-tertile inter-
action p values were nonsigniﬁcant.
To explore this observation further, we considered
absolute risk differences, where statistically signiﬁ-
cant risk reductions with icosapent ethyl across all
tertiles and larger reductions in the highest tertile
were again observed; but here, unadjusted cross-
tertile interaction p values were p ¼ 0.12 for ﬁrst
events and p ¼ 0.03 for total events. The highest
baseline triglyceride tertile likely impacted the
interaction p values, with 21.0 (p < 0.0001) fewer
ﬁrst events (45.3 vs. 66.3) and 48.3 (p < 0.0001)
fewer total events (64.4 vs. 107.4) per 1,000 patient-
years for icosapent ethyl versus placebo, compared
with 11.0 (p ¼ 0.0055) (39.6 vs. 50.5) and 10.7
(p ¼ 0.0168) (45.9 vs. 56.7) fewer ﬁrst events, and
21.2 (p ¼ 0.0028) (56.4 vs. 74.5) and 21.3 (p ¼ 0.0113)
(63.2 vs. 86.8) fewer total events in the lowest
and middle tertiles, respectively, with icosapent
ethyl compared with placebo. In the full cohort, 14.0
ﬁrst events (43.4 vs. 57.4) and 30.2 total events (61.1
vs. 88.8) were avoided per 1,000 patient-years with
icosapent ethyl compared with placebo (p < 0.0001
for both).
This suggestion of potential additional beneﬁt in
patients with higher triglycerides may be due to a
higher baseline risk (triglyceride elevation as a
marker of risk) and/or greater icosapent ethyl beneﬁt
in patients with higher triglycerides. Further studies
are needed to distinguish the contributions of each
aspect to the large risk reductions with icosapent
ethyl. These REDUCE-IT analyses may help redeﬁne a
lower “normal” triglyceride level, analogous to the
redeﬁnition of lower normal LDL cholesterol as data
emerged supporting therapeutic beneﬁts of LDL
lowering with statins, ezetimibe, and PCSK9
inhibitors.
In conclusion, icosapent ethyl 4 g/day signiﬁ-
cantly reduced ﬁrst and total ischemic events in
J O U R N A L O F T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y VO L . 7 4 , N O . 8 , 2 0 1 9
I S S N 0 7 3 5 - 1 0 9 7
statin-treated patients with well-controlled LDL
cholesterol across a wide range of baseline tri-
glycerides, suggesting that the cardiovascular bene-
ﬁts of icosapent ethyl are tied primarily to baseline
risk and non–triglyceride-related effects. Nonethe-
less, while approximately 10% of REDUCE-IT patients
had triglycerides currently considered normal
(<150 mg/dl), almost all REDUCE-IT patients had
triglycerides greater than what might now be
considered an optimal level of <100 mg/dl. Future
REDUCE-IT biomarker studies and data analyses will
explore the potential mechanisms behind the sub-
stantial reductions in cardiovascular risk observed
with icosapent ethyl.
FIGURE 1 Effect of Icosapent Ethyl on First and Total Ischemic Events by Baseline Triglyceride Tertiles
B
TOTAL EVENTS – Primary Composite
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0.2
n/N (%)
705/4089 (17.2)
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246/1370 (18.0)
226/1338 (16.9)
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n/N (%)
901/4090 (22.0)
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283/1326 (21.3)
327/1382 (23.7)
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0.79 (0.66–0.94)
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0.68 (0.57–0.80)
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TIME TO FIRST EVENT – Primary Composite
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Icosapent Ethyl
Better
Placebo
Better
1.0 1.4 1.8
The primary composite endpoint event consists of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or hospitalization
for unstable angina. First events (A) and subsequent (total) events (B) are depicted across tertiles of baseline triglycerides. CI ¼ conﬁdence interval; HR ¼ hazard ratio;
ITT ¼ intent to treat; RR ¼ rate ratio.
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